| Literature DB >> 29057060 |
Masahito Abe1,2, Mabel Seto1,2, Rocco G Gogliotti1,2, Matthew T Loch1,2, Katrina A Bollinger2, Sichen Chang2, Eileen M Engelberg1,2, Vincent B Luscombe1,2, Joel M Harp3, Michael Bubser1,2, Darren W Engers1,2, Carrie K Jones1,2,4, Alice L Rodriguez1,2, Anna L Blobaum1,2, P Jeffrey Conn1,2,4, Colleen M Niswender1,2,4, Craig W Lindsley1,2,4.
Abstract
Herein, we report the structure-activity relationships within a series of mGlu7 PAMs based on a pyrazolo[1,5-a]pyrimidine core with excellent CNS penetration (Kps > 1 and Kp,uus > 1). Analogues in this series proved to display a range of Group III mGlu receptor selectivity, but VU6005649 emerged as the first dual mGlu7/8 PAM, filling a void in the Group III mGlu receptor PAM toolbox and demonstrating in vivo efficacy in a mouse contextual fear conditioning model.Entities:
Keywords: Positive allosteric modulator (PAM); Rett syndrome; VU6005649; cognition; metabotropic glutamate receptor 7 (mGlu7)
Year: 2017 PMID: 29057060 PMCID: PMC5641958 DOI: 10.1021/acsmedchemlett.7b00317
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345